EGFR-TKI治疗EGFR敏感突变的晚期肺鳞癌的疗效分析
DOI: 10.3971/j.issn.1000-8578.2015.09.011
Keywords: 肺鳞癌,EGFR突变,EGFR-TKI,Advances of FGF/FGFR Signaling Pathway in Targeted Therapy for Squamous Cell Lung Cancer,Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer,Expression and Significance of NapsinA,TTF-1,CK5/6,CK7 and P63 in Biopsy Specimen by Bronchoscope of Non-small Cell Lung Cancer,Clinical Significance of Cyfra21-1 Analysis Combined with SELDI-TOF-MS Technology in Lung Squamous Carcinoma,Expression and Clinical Significance of Annexin-1 in Lung Squamous Carcinoma Tissues,RNA Interference-mediated Significant Enhancement of Apoptosis in Yunnan Gejiu Lung Squamous Carcinoma Cells(YTMLC) by siRNA Expression Vector Targeting Survivin Gene,The Expression and Clinical Significance of p53 and Prol iferating Cell Nuclear Antigen (PCNA) in Lung Squamous Cell Carcinoma,The Value of Free Sailic Acid(FSA)Determination in Lung Cancer Diagnosis
Abstract:
摘要 目的 探讨表皮生长因子酪氨酸激酶抑制剂（Epidermal growth factor receptor-tyrosine kinase inhibitor, EGFR-TKI）治疗EGFR敏感突变的晚期肺鳞癌患者的疗效。方法 收集20例四川大学华西医院经病理确诊、EGFR检测敏感突变、并接受EGFR-TKI治疗的Ⅳ期或术后复发转移肺鳞癌患者，分析其与EGFR-TKI的疗效关系。结果 20例EGFR敏感突变的晚期鳞癌患者接受EGFR-TKI治疗，随访资料完整。10例19-del（+），8例L858R（+），1例同时存在外显子21（L858R）点突变和外显子20（T790M）突变，1例外显子18（G719X）突变。其中部分缓解（PR）9例，疾病稳定（SD）7例，疾病进展（PD）4例。客观缓解率（ORR）45%，疾病控制率80%，中位无进展生存期（mPFS）为5.0月，中位生存期（mOS）为14.7月。结论 EGFR-TKI对部分EGFR敏感突变的鳞癌患者有一定疗效。在临床工作中，应重视这部分患者的EGFR基因检测，以便明确获益的患者
Full-Text
